COO · Q2 2025 Earnings

Management's posture this quarter is the cleanest example of a company cutting its market assumptions while simultaneously claiming share gains will fill the gap — a tension that ran through every analyst exchange.

The market growth reset is the headline shift. Cooper walked back its contact lens market assumption to 4–6% from 5–7%, explicitly framing the new range as "the industry's historical growth range which we saw for many years pre-COVID" — in other words, the post-pandemic tailwind is over. Fertility took a sharper cut, from mid-to-upper single digits to low single digits. The framing was defensive: "Similar to other companies, we're dealing with a more complex global operating environment, but we're controlling what we can by executing well." Translation: the market assumptions Cooper had been building forecasts on were too generous.

The fertility narrative is now bifurcated in a way it wasn't before. Management paired sharp near-term caution — clinics delaying capex, consumers stretching cash, Asia-Pac cycles down YoY — with the line "we remain incredibly bullish on the long-term prospects for fertility as the underlying growth fundamentals remain intact." That gap between "soft and getting softer right now" and "structurally great long-term" is wider than it has been, and it's the kind of framing companies use when they don't want to commit to a near-term floor.

Capacity is no longer the constraint; share gains are the story. "With improved capacity, we're back to being aggressive, and that can be seen in a number of areas." This is a meaningful pivot — the prior multi-year narrative around CooperVision was capacity-limited supply. Now management is leaning hard on MyDay fittings, MySite ramp ($100M+ run rate, 30–35% growth target), and private label expansion to deliver ~150bps of market outperformance (6.5% midpoint vs. 5% market).

Paragard reverses. After +15% growth in H1 driven heavily by channel fill, management now guides mid-teens decline in Q3 before a flattish Q4. The full-year low-to-mid single-digit result hides a dramatically choppy quarterly path, and analysts will need to model the H2 air pocket carefully.